+40 264 433427


A Case of Duodenal Neuroendocrine Carcinoma Treated with Amrubicin as Second-line Chemotherapy

download Full Article (PDF file)

Tadahisa Inoue, Hitoshi Sano, Takashi Mizushima, Hirotada Nishie, Hiroyasu Iwasaki, Fumihiro Okumura

Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan



We present the case of a Japanese man in his 60s with duodenal neuroendocrine carcinoma with distant metastases. Chemotherapy with irinotecan plus cisplatin was initiated as a first-line regimen. However, disease progression was observed after only two cycles. Therefore, amrubicin was administered as a second-line chemotherapy. The patient showed a long-term effect of amrubicin therapy, and the best response was a partial response after seven cycles. For duodenal neuroendocrine carcinoma, amrubicin therapy can be considered an effective treatment option as salvage chemotherapy.

Key words: duodenal neuroendocrine carcinoma – amrubicin – chemotherapy.